QuidelOrtho Reports Q2 Loss, Negative Operating Cash Flow, Confirms Slashed Full-Year Guidance

summarizeSummary

QuidelOrtho's Q2 2026 10-Q confirms an improved net loss but highlights a concerning shift to negative operating cash flow and increased debt, reinforcing the negative full-year guidance previously announced.

check_boxKey Events · Earnings and Guidance · QDEL

• Q2 Financial Performance

  Reported Q2 2026 revenue of $630.9 million and a net loss of $92.9 million, an improvement from the prior year's loss of $255.4 million.

• Negative Operating Cash Flow

  Shifted to using $143.6 million in cash from operations year-to-date, compared to generating $18.8 million in the prior year, indicating a significant liquidity challenge.

• Increased Borrowings

  Long-term borrowings increased to $2,535.4 million from $2,471.9 million, and revolving credit facility usage rose to $250.0 million from $80.0 million at year-end 2025.

• Strategic Initiatives Detailed

  Provided further details on the $174.6 million LEX Diagnostics acquisition and ongoing restructuring efforts, including the wind-down of the U.S. donor screening portfolio and SAVANNA platform exit.

auto_awesomeAnalysis · QDEL · Life Sciences

This 10-Q details QuidelOrtho's Q2 2026 financial performance, confirming the previously announced revenue of $630.9 million and an improved net loss of $92.9 million compared to the prior year. However, the company experienced a significant shift to negative operating cash flow, using $143.6 million year-to-date, and increased its revolving credit facility usage. The filing also elaborates on the strategic initiatives like the LEX Diagnostics acquisition and the ongoing restructuring, but the overall outlook remains challenged by a weaker respiratory season and pricing pressures in China, consistent with the recently slashed full-year guidance.